Biogen's growth was projected to remain flat through the 2030s before recent strategic moves changed the outlook
CEO Chris Viehbacher announced the company is focusing on early-stage development and research assets to build the next generation of growth
Biogen acquired kidney disease biotech Apellis for $5.6 billion to strengthen its late-stage pipeline in lupus, nephrology, and neurology
The company has bolstered its early pipeline through licensing collaborations, including deals with Vanqua Bio, Dayra Therapeutics for immunology, and a $46 million RNAi-based therapy collaboration with City Therapeutics
Q1 2026 earnings showed strong performance with Leqembi sales rising 74% year-over-year to $168 million globally and overall revenue growth of 2% year-over-year
The company is prioritizing research-stage projects and Phase 1 assets rather than later-stage acquisitions to fill gaps in its thin early-stage pipeline